Increase your odds in fighting cancer with Hi-Precision Diagnostic tool - test CA-62 marker of epithelial carcinomas - the successor of RecAf technology

gallery/MEC-4139

The identifying the receptor(it's part) of alphafetoprotein (RecAf) in blood was done by Ricardo Moro nearly two decades ago. The technology is based on its ability to detect specific Cancer antigen CA-62 expressed on epithelial cancer cells. More than 5,000 samples were

studied using CA-62 test with materials from cancer

research centers in Europe, the USA, Canada and Russia.

•Epithelial types of cancer such as Breast cancer, Prostate cancer, Ovarian cancer, Lung cancer, Colorectal cancer etc.

•Over 90% sensitivity with 95% specificity (~5% false positives)

•Validated in over 15 studies

•Higher precision over PSA, mammography and other


cancer diagnostic tests

The company JVS Diagnostics LLC - is SPV created by our team to develop and organize the manufacturing of the immunochemical diagnostic


test kits targeted for early cancer detection.

The major product of the company is the diagnostic test kit based on the innovative Marker of Epithelial Carcinomas MEC, which appears on the surface of

the malignant epithelial cells from the very onset of


oncogenesis.
Thus, the innovativeness of the “MEC" technology

and its competitive advantage over other cancer

markers is that it is very effective method for early

detection of the epithelial tumors. The test can be performed in combination with other registered cancer markers such as PSA, CA-125, CA-15-3, CEA or



as independent screening instrument that significantly increases overall survival of the patients.

In addition to the early detection of cancer, the

technology “MEC" can also be effectively used for cancer monitoring in patients with advanced cancer and for the evaluation of the treatment effectiveness, as well as for the relapse diagnosis in patients, as it was previously shown in a blind clinical study. The dynamics of the MEC biomarker’s changes during the course of chemotherapy in patients with advanced cancer of the stomach and the lung showed a good correlation (75%) with the

patient’s overall response status according to the

RECIST criteria. It was shown that there is a

possibility of using the technology “MEC" for monitoring of the cancer disease and for assessing

of an ongoing systemic treatment.
The test kit is designed for:
1) Detection of the early stages of epithelial cancer, such as breast cancer, prostate cancer, lung cancer, stomach cancer, ovarian cancer, etc.
2) Monitoring the treatment of cancer patients

using the dynamics of the CA-62 marker during chemotherapy. This allows to quickly (within 1

month) identify the inefficiency of some therapy


and to change the course.

gallery/IMG-20180726-WA0009-9025
gallery/IMG-20180726-WA0015-1839
gallery/IMG-20180726-WA0030-2568

Pilot clinical studies on patients with different stages of prostate cancer, breast cancer, and

ovarian cancer using a new cancer marker MEC showed >90% Sensitivity with 95% Specificity of the

test for early stages of cancer. Monitoring the

dynamics of the cancer marker CA-62 for the

patients with advanced stages of cancer during a course of chemotherapy have demonstrated a very

good correlation between expression of CA-62

marker and a clinical status of the patient

according to the criterion RECIST. Within the

framework of this project an industrial set of reagents will be developed for cancer treatment monitoring and for early detection of cancer based

on the MEC biomarker. The test system is expected

to be registered in RF and abroad, as well as

organization of its manufacturing

gallery/Cutoff_mec-2137
gallery/recist-9385



The  Project Dynamics

The report "The possibility to use the epithelial carcinoma marker CA-62 for the early detection of malignant epithelial tumors" during Skolkovo

session headed by the Academician Alexander G.

Rumyantsev was done in Russian Oncological

Congress by Janneta R. Tcherkassova - the JVS CEO.


15/11/2018

JVS DIAGNOSTICS llc have took part in Russian Oncological Congress

gallery/1554126106725-6908


17/10/2018

JVS DIAGNOSTICS llc during the Open



Innovations 2018 has declared the finalizing the first round of investments

The UCT inc Toronto, Canada has finished the first round of investments to develop its JVS Diagnostics subsidiary. This declaration was done during Open Innovations Forum and

shared by media. The first press release was published by

Forbes Russia. Also The Skolkovo Innovation Center has

shared it's own press release.

gallery/forum_3-2619